Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months of 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Emergent BioSolutions (EBS) Tops Q2 EPS by 19c
August 2, 2018 4:41 PM EDTEmergent BioSolutions (NYSE: EBS) reported Q2 EPS of $1.07, $0.19 better than the analyst estimate of $0.88. Revenue for the quarter came in at $220.2 million versus the consensus estimate of $208.57 million.
GUIDANCE:
Emergent BioSolutions sees FY2018 revenue of $715-755 million, versus the consensus of... More
